Ipca Laboratories Ltd. Share Price

FPIs pour Rs 15,800 crore into pharma since July

Foreign portfolio investors invested ₹15,800 crore into Indian pharmaceutical shares between July and the first half of September. Despite this sector-wide inflow, IPCA Laboratories Limited

, Laurus Labs Limited (LAURUSLABS), and Glenmark Pharmaceuticals Limited (GLENMARK) were the top losers in the Nifty Pharma index on September 25. A ₹15,800 crore inflow over roughly two and a half months represents a substantial, sustained allocation into one sector, not a single day's rotation. Yet on the same day this figure was reported, three specific pharma names sat at the bottom of the sector index, moving opposite to the direction the aggregate flow data would suggest. Aggregate buying and individual stock performance can diverge sharply, even within the same sector and the same time window. Sector-wide FPI inflow data tells you capital is broadly rotating into pharma as a theme, but it says nothing about which specific companies within that sector are receiving that capital versus which ones are being sold even as the sector aggregate rises. IPCA Laboratories, Laurus Labs, and Glenmark Pharmaceuticals underperforming on the same day this inflow figure was published means either the money is concentrated in a narrower set of pharma names, or these three carry company-specific concerns strong enough to offset the sector tailwind. I would want to see the actual FII shareholding change for these three specific companies before assuming the sector inflow number applies evenly. A single sector-level statistic can mask real dispersion underneath it, exactly the kind of gap worth checking rather than assuming. My stance: the sector-level inflow is real, but I am not extending that as a positive read to these three specific names without their own company-level flow data. Watching individual shareholding disclosures for IPCA Laboratories, Laurus Labs, and Glenmark Pharmaceuticals before forming a view on any of them.

See More

Ipca Labs: Pullback Enters the 4 Sept Entry Zone, Kotak Fund

Ipca Laboratories Limited shares have pulled back from the 4 September close of Rs 1,942.99 to Rs 1,920.20 today, with a session low of Rs 1,889.20 inside the Rs 1,880 to 1,910 accumulation zone identified in the 4 September results post. What changed since 4 September: Decline of 3.59% over the month on pharma sector rotation, no company-specific news Session low Rs 1,889.20 is the first clean test of the Rs 1,880 to 1,910 support since the post Kotak Midcap Fund added 1.23 crore shares in August 2026, new to the register 52-week high Rs 1,975.64; the record high on exchange Rs 2,001.50 remains unretested Q1 FY27 recap: revenue Rs 2,788 crore, up 21%; EBITDA margin 22.88% vs 18.39%; PAT Rs 401.9 crore, up 72%; guidance raised to 14 to 16% revenue growth; medium-term margin target 25 to 26%; brokerage targets Rs 2,000 to 2,118. Ipca Labs [][***** shares trade at Rs 1,920.20 (16 Sep 2026, 03:30 PM IST), up 47.3 percent over one year and 3.6 percent over the past month. P/E 37.2; PEG 0.68; sector P/E 44.64. My view: the 4 September post said the easy money was made and identified Rs 1,880 to 1,910 as the entry. Both the zone and the thesis are unchanged. The session low of Rs 1,889.20 is inside the zone. At 37.2x, PEG 0.68, below the sector's 44.64x and with the guidance raise in the price, this is the entry the post described. Accumulate in the Rs 1,889 to 1,920 zone; invalidation on a close below Rs 1,880; Rs 1,975 to 2,001 the band to clear. Disclosure: Vijay Kumar Gupta, SEBI Registered Research Analyst, INH000020226, Vijay Gupta Advisory. SEBI registration and NISM certification do not guarantee performance or assure returns. Securities markets are subject to market risks. No holdings in the subject company.

See More

Ipca Labs Q1 FY27: Profit Up 72%, Guidance Raised

Ipca Laboratories Limited reported Q1 FY27 results for the June 2026 quarter on 13 August. Q1 FY27 numbers (consolidated): Revenue: Rs 2,788 crore, up 21% YoY; 7.7% above consensus EBITDA: Rs 638 crore, up 50% YoY; margin 22.88% vs 18.39% PAT: Rs 401.9 crore, up 72% YoY; EPS Rs 15.84 vs Rs 12.43 expected Domestic formulations up 13%; exports Rs 603 crore, up 34%, Europe up 70%; API up 30% Guidance raised: FY27 revenue growth to 14 to 16% from 12 to 13%, EBITDA margin to about 23% from 22%, with 25 to 26% targeted medium term. Two footnotes: institutional exports doubled partly on Rs 40 crore deferred from March, and the weak rupee was a net margin positive. JM Financial, Nuvama and Prabhudas Lilladher hold Buy, targets Rs 2,000 to 2,118. Ipca Labs [][***** shares closed at Rs 1,942.99 on the linked page on 3 September 2026, up 12 percent since results, 39 percent in a year, after a record Rs 2,001.50 in recent sessions. P/E 37.6; PEG 0.7. My view: a deserved re-rating that the market completed before you could act on it. The beat is broad and the guidance raise credible, with Unichem's drag fading and API and Europe running; strip the deferred March shipments and exports still grew about 25 percent. But at 37.6x and a record high, with the street's own targets 3 to 9 percent away, the easy money is made. Hold; fresh entry on a pullback to Rs 1,880 to 1,910, the post-results base, or on evidence the 25 to 26 percent margin path arrives early. Levels: Rs 1,880 to 1,910 support; Rs 1,733 to 1,800 the pre-results shelf; Rs 2,001 the record to clear. Disclosure: Vijay Kumar Gupta, SEBI Registered Research Analyst, INH000020226, Vijay Gupta Advisory. SEBI registration and NISM certification do not guarantee performance or assure returns. Securities markets are subject to market risks. No holdings in the subject company.

See More

IPCA Laboratories Limited Results Analysis-Q1FY27

Financial performance and key Operating Metrics (Consolidated) : Operating Revenue for Q1FY27 is Rs. 2,788 Crs., 20.76% growth YoY, Total Income is Rs. 2,813 Crs., 20.15% growth YoY, Gross Profit is Rs. 1,991 Crs., 23.09% growth YoY, EBITDA is Rs. 670 Crs., 49.08% growth YoY, EBITDA Margin is 24% improved by 483 basis points YoY, PBT Rs. 572 Crs., 73.09% growth YoY, PAT Rs. 423 Crs. 80.36% growth YoY. On QoQ basis Operating Revenue is up by 16.73%, Total Income is also up by 13.34%, Gross Profit is up by 17.32%, EBITDA is up by 15.91%, PBT is up by 41.45% and PAT is also up by 36.65%. Q1 as strong execution despite logistics/supply volatility. Almost all businesses has delivered good growth for the company for the first quarter. Domestic formulations revenue: +13% YoY to ~INR 1,082 cr (vs INR 961 cr). Overall exports: +34% YoY to ~INR 603 cr (vs ~INR 450 cr). API Business: Solid Growth; Capacity Constraints Driving Capex FY27 revenue growth: Previously 12–13%, now upgraded to ~14–16%. Rationale: “upside… from the overall generic business, India business performing very well… API business has given good growth.” FY27 consolidated EBITDA margin: Raised from ~22% to ~23%: “because of better performance.” Headwinds: container shortages, shipment delays, sharp freight inflation, raw-material price volatility, and FX-linked opex inflation in overseas operations.

See More

Ipca Laboratories Ltd shares surged up to 12% on 17 August 2026,

Ipca Laboratories Ltd shares surged up to 12% on 17 August 2026, hitting a record high of ₹1,945 after reporting a 72% jump in quarterly profit and upgrading FY27 growth guidance. Brokerages including JM Financial, Nuvama, and Prabhudas Lilladher raised their target prices to ₹2,000–₹2,118, maintaining a ‘Buy’ rating. 📊 Q1 FY27 Financial Highlights Metric Q1 FY27 (June 2026) YoY Change Notes Revenue ₹ 2,788.10 crore +21% Strong domestic & export growth EBITDA ₹ 637.94 crore +50% Margin expanded 600 bps to 24% Net Profit (PAT) ₹ 401.89 crore +72% Driven by branded formulations & API EPS ₹ 15.84 +72% Analysts expected ₹ 12.43 — beat estimates Domestic formulations grew 13% YoY, branded generics 16%, and API exports 33%. The institutional export business doubled to ₹ 120 crore, though ₹ 40 crore was deferred from March shipments. 📈 Guidance & Outlook Revenue growth FY27: Raised to 14–16% (from 12–13%). EBITDA margin FY27: Upgraded to 23% (from 22%). US growth: Expected 15–17% with 7–8 new launches via Unichem subsidiary. FY29 target: Consolidated EBITDA margin 25–26%. Valuation: Trading at ~25× FY28E P/E; brokerages see scope for further re‑rating. 🧪 Segment Performance India Business: ₹ 1,082 crore revenue (+13% YoY). Export Business: Up 34% YoY; Europe grew ~70%. API Segment: Strong recovery in both domestic and export markets. Unichem Laboratories: Maintains 10% growth guidance and 13% EBITDA margin. 💹 Brokerage Ratings (17 Aug 2026) Brokerage Rating Target Price Key Comment JM Financial Buy ₹ 2,118 “Margins set to improve to 25–26% mid‑term.” Nuvama Institutional Equities Buy ₹ 2,025 “Strong mix change and operating leverage to drive profitability.” Prabhudas Lilladher Buy ₹ 2,000 “Recovery in API segment and steady domestic growth support valuation.”

See More

Ipca Labs Scales Fresh All-Time High, Pares Gains After Hitting the Peak

Ipca Laboratories [

] surged up to 12.18% intraday today, hitting a fresh all-time high of Rs 1,945.10 — marginally above its previous peak of Rs 1,944.90 set on 17 July 2026. The stock pulled back immediately after touching the new high and settled with a gain of 8.67% for the day. The sharp intraday surge followed by a pullback right at the new high is a classic sign of profit-booking near a key resistance zone, even as the stock closed well in the green, reflecting overall strong buying interest heading into the session's close. 📌 Disclaimer: This content is for information only and not investment advice. Investments in securities market are subject to market risks. Read all the related documents carefully before investing. Please consult a SEBI-registered advisor before making any investment decisions.

See More